{"title":"Development and External Validation of Machine Learning-based Models for Predicting Survival Outcomes in Endometrial Cancer: A Population-based Study.","authors":"Munetoshi Akazawa, Kazunori Hashimoto, Hiroaki Nagano","doi":"10.21873/anticanres.17715","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Most endometrial cancers are early-stage cancers with a good prognosis, but the prognosis for recurrent endometrial cancer is poor. Accurate prognostication is essential for the management of patients with cancer. This study aimed to assess the survival outcome of endometrial cancer using machine learning.</p><p><strong>Materials and methods: </strong>We used data from the Surveillance, Epidemiology, and End Results (SEER) database, constructing machine learning models to predict the 5-year overall survival (OS) and cancer-specific survival (CSS). The variables included patient demographics, pathological factors, and therapeutic factors.</p><p><strong>Results: </strong>The OS rates of 71,506 patients and the CSS rates of 66,368 patients were included. For the prediction of OS, the best machine learning model achieved a class accuracy of 0.86 (95% CI=0.85-0.87) and an area under the curve (AUC) of 0.83 (95% CI=0.82-0.84) in the internal validation set (SEER dataset). In the external validation set of 149 patients, the best model achieved a class accuracy of 0.85 (95% CI=0.86-0.86) and an AUC of 0.85 (95% CI=0.85-0.86). The model predicted CSS more accurately than OS.</p><p><strong>Conclusion: </strong>Using machine learning, we were able to predict the prognosis of patients with endometrial cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 8","pages":"3543-3551"},"PeriodicalIF":1.7000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17715","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background/aim: Most endometrial cancers are early-stage cancers with a good prognosis, but the prognosis for recurrent endometrial cancer is poor. Accurate prognostication is essential for the management of patients with cancer. This study aimed to assess the survival outcome of endometrial cancer using machine learning.
Materials and methods: We used data from the Surveillance, Epidemiology, and End Results (SEER) database, constructing machine learning models to predict the 5-year overall survival (OS) and cancer-specific survival (CSS). The variables included patient demographics, pathological factors, and therapeutic factors.
Results: The OS rates of 71,506 patients and the CSS rates of 66,368 patients were included. For the prediction of OS, the best machine learning model achieved a class accuracy of 0.86 (95% CI=0.85-0.87) and an area under the curve (AUC) of 0.83 (95% CI=0.82-0.84) in the internal validation set (SEER dataset). In the external validation set of 149 patients, the best model achieved a class accuracy of 0.85 (95% CI=0.86-0.86) and an AUC of 0.85 (95% CI=0.85-0.86). The model predicted CSS more accurately than OS.
Conclusion: Using machine learning, we were able to predict the prognosis of patients with endometrial cancer.
期刊介绍:
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.